Follow us on Twitter
twitter icon@FreshPatents


Steoporosis patents

      

This page is updated frequently with new Steoporosis-related patent applications.




 Urea compounds and their use as enzyme inhibitors patent thumbnailUrea compounds and their use as enzyme inhibitors
Or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, parkinson's disease, levodopa-induced dyskinesia, huntington's disease, gilles de la tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis..

 Fibronectin based scaffold domain proteins that bind to myostatin patent thumbnailFibronectin based scaffold domain proteins that bind to myostatin
The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, copd, chronic kidney disease, heart failure, myocardial infarction, and fibrosis.
Bristol-myers Squibb Company


 Use of peptidic drugs for osteoporosis treatment and bone regeneration patent thumbnailUse of peptidic drugs for osteoporosis treatment and bone regeneration
The present invention provides osteogenic peptides derived from the cementum-derived attachment protein (hacd1/cap) and another derived from the cementum protein 1 (cemp1) and pharmaceutical compositions of these peptides for the prevention and treatment of osteopenia and osteoporosis. These peptides increase bone mineral density in an osteoporotic model and without in vivo side effects, demonstrating clinical effectiveness in the prevention and treatment of osteopenia and osteoporosis in vivo as well as bone repair and/or regeneration..
Universidad Nacional Autonoma De Mexico


 Furo[3,4-b]pyran compounds and pharmaceutical uses patent thumbnailFuro[3,4-b]pyran compounds and pharmaceutical uses
Furo[3,4-b]pyran compounds similar in chemical structure to the natural product known as tan-2483b and their use for treating cancer, osteoporosis, type 2 diabetes, or immune diseases.. .
Victoria Link Limited


 Peptides for preventing or treating bone diseases and use thereof patent thumbnailPeptides for preventing or treating bone diseases and use thereof
The present disclosure relates to a novel peptide for preventing or treating bone diseases. Further, the present disclosure relates to a polynucleotide encoding the peptide, a vector including the polynucleotide, a host cell transformed by the vector, and a method for producing the peptide by using the host cell.
Kyungpook National University Industry - Academic Cooperation Foundation


 Novel peptides for preventing or treating bone diseases and use thereof patent thumbnailNovel peptides for preventing or treating bone diseases and use thereof
The present disclosure relates to a novel peptide for preventing or treating bone diseases. Further, the present disclosure relates to a polynucleotide encoding the peptide, a vector including the polynucleotide, a host cell transformed by the vector, and a method for producing the peptide by using the host cell.
Kyungpook National University Industry - Academic Cooperation Foundation


 Compositions and methods for treatment of osteoporosis and other indications patent thumbnailCompositions and methods for treatment of osteoporosis and other indications
The present invention generally relates to compositions and methods for treatment of subjects having or at risk of osteoporosis or other conditions. In some cases, the composition may include nitric oxide.
Transdermal Biotechnology, Inc.


 Selective elimination of erosive cells patent thumbnailSelective elimination of erosive cells
The current invention relates to the treatment of diseases characterized by cartilage destruction and/or bone erosion. In particular the present invention relates to the treatment of osteoarthritis, osteoporosis, psoriatic arthritis or rheumatic arthritis with an anti-nkg2a antibody..
Novo Nordisk A/s


 Compositions and methods for controlled localized delivery of bone forming therapeutic agents patent thumbnailCompositions and methods for controlled localized delivery of bone forming therapeutic agents
The present invention provides compositions and methods for providing controllable local delivery of a therapeutic agent to promote bone formation. In certain embodiments, the invention is used as a treatment for a subject with osteoporosis, bone cancer or bone fracture.
University Of Rochester


 Use of organic sulphur, antioxidants, and amino acids in conjunction with exercise and electromagnetic stimulation to treat osteoporosis patent thumbnailUse of organic sulphur, antioxidants, and amino acids in conjunction with exercise and electromagnetic stimulation to treat osteoporosis
Through the use of a combination of naturally occurring substances, application of mechanical energy by way of exercise, and application of a pulsed electromagnetic field (pemf), new bone formation at lines of stress can be promoted. This bone forming activity is useful in the treatment and prevention of osteoporosis.

Calcium supplement having enhanced absorption

Dietary calcium supplements comprising highly bioavailable forms of calcium carbonate and methods of using these calcium carbonate forms to improve calcium balance, strengthen bones, and prevent, treat, and/or ameliorate bone loss associated with osteoporosis are provided.. .
Delavau Llc

Oxazolidine-based compound and selective androgen receptor agonist comprising same

Provided are novel selective androgen receptor agonists, a preparation method thereof, and a pharmaceutical composition including the same at a pharmaceutically effective amount. The selective androgen receptor agonists according to the present invention act on androgen receptors to increase androgen activity, thereby being usefully applied as a therapeutic and prophylactic agent for diseases or conditions, of which symptoms may be improved or may respond to treatment by increased activities of androgen receptors, namely, a variety of hormone-related diseases in male and female, muscle wasting disorders, osteoporosis, etc..
Dong-a St Co., Ltd.

Inhibitor of inflammatory conditions

The invention relates to boswellia frereana and particularly an extract of same for treating a range of inflammatory disorder or conditions selected from the group comprising: inflammatory bowel disease (ibd), all forms of muscular dystrophy especially duchenne muscular dystrophy, sepsis, sepsis syndrome, osteoporosis, ischemic injury, graft vs. Host disease, reperfusion injury, asthma, diabetes, cancer, myelogenous and other leukemias, psoriasis and cachexia, alzheimer's disease, demyelinating neurological disorders including multiple sclerosis, acetylcholinesterase mediated disorders, retinal disorders, neurological, retinal, and muscular disorders..
Compton Developments Ltd.

Isoform nell-1 peptide

This application is drawn to a method of using an isoform nell-1 peptide, and compositions thereof for bone formation or for treating, preventing, or ameliorating osteoporosis.. .
The Regents Of The University Of California

Method for preparing osteoblasts and osteoblast inducer

An object of the present invention is to provide a method for preparing osteoblasts that are applicable, without causing risk of canceration, to bone defect repair or to the treatment of bone resorption, fracture, osteoporosis, or the like. To solve this problem, the present invention provides a method for preparing osteoblasts, the method comprising culturing mammal differentiated somatic cells in a medium in the presence of at least one compound selected from the group consisting of (1) statin compounds, (2) casein kinase 1 inhibitors, (3) camp inducers, and (4) histone methyltransferase inhibitors, to convert the somatic cells into osteoblasts..
Kyoto Prefectural Public University Corporation

Pparg modulators for treatment of osteoporosis

The invention provides methods of treatment of a progressive bone disease, such as osteoporosis, paget's disease, multiple myeloma, or hyperparathyroidism, comprising administration of an effective amount of a non-agonist pparg modulator to a patient afflicted with the disease.. .
University Of Toledo

Irisin for care and prevention of osteoporosis

Object of the present invention is the use of irisin for the treatment and/or prevention of osteoporosis. In particular, the present invention refers to the use of recombinant irisin for the treatment and/or prevention of osteoporosis..
Universita' Politecnica Delle Marche

Tumor eradication by inositol-tripyrophosphate

The present invention relates to various salts of inositol tripyrophosphate including the calcium, lithium, beryllium, magnesium, potassium, strontium, barium, rubidium and cesium salts of inositol tripyrophosphate, compositions comprising these salts, methods of making the various salts, and methods of use of the above salts. Methods of use include administering the above salts in an effective amount in individuals for the treatment of various types of cancers, alzheimer's disease, stroke and osteoporosis..
Normoxys, Inc.

Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)

Novel forms of [r, (r*,r*)]-2-(4-fluorophenyl)-β,δdihydroxy-5-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1-h-pyrrole-1-heptanoic acid hemi calcium salt designated form xx, form xxi, form xxii, form xxiii, form xxiv, forms xxv, form xxvii, form xxviii, form xxxix, and forms xxx, characterized by their x-ray powder diffractor, solid state nmr, and/or raman spectroscopy are describes as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia (bph) and alzheimer) disease.. .
Warner-lambert Company Llc

Red light implants for treating osteoporosis

A method of irradiating spinal tissue with red/nir light, comprising: inserting a cannulated device defining a bore into the spinal column, wherein the bore contains an optically transparent substrate adapted to emit red/nir light, and transmitting nir/red light through the substrate to irradiate tissue within the spinal column.. .
Depuy Synthes Products, Inc.

Citrate-rich calcium-magnesium supplement and uses thereof

Disclosed is an effervescent preparation of calcium and magnesium with additional citric acid in a defined ratio. Also disclosed is the use of these compositions to raise cardioprotective citrate and magnesium in serum to help prevent heart attacks from calcium supplements, and to provide bioavailable calcium and magnesium to prevent osteoporosis-related fractures and low blood magnesium from the use of proton pump inhibitors..
The Board Of Regents Of The University Of Texas System

Amphiphilic peptide matrices for treatment of osteoporosis

The present invention provides methods for prevention, prevention of progression, and treatment of osteoporosis and pre-osteoporotic conditions comprising direct administering to osteoporotic bone of a composition comprising amphiphilic peptides and peptide matrices thereof, useful in promoting biomineralization, local osteoporotic medications and inducing bone repair.. .
Ben-gurion University Of The Negev Research And Development Authority

Bone and joint protection composition and use thereof

The invention relates to a bone and joint protection composition and use thereof. According to the composition, the four chinese medicinal herbs eucommiae cortex, achyranthis bidentatae radix, astragali radix and chuanxiong rhizoma are used, and the effects of enhancing the bone density, preventing and relieving osteoporosis, restraining the activity of osteoclast, promoting the function of bone cells, increasing the formation of calcified bone, promoting cartilage repair, delaying joint recession and repairing joint damage are achieved through multiple approaches and multiple levels.
Infinitus (china) Company Ltd.

Novel cannabinoid receptor 2 (cb2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases

Wherein: r1 and r2 are independently h, alkyl, or alkenyl; r3 is alkyl, alkenyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl; r4 and r5 are independently a bond, alkylenyl, or alkenylenyl; each r6 and r7 is independently selected from the group consisting of oh, f, cl, br, i, (c1-c6)alkyl, alkoxy, amino, cooh, conh2, so3h, po3h2, cn, sh, no2 and cf3; and p and q are independently 0, 1, 2, 3, 4, or 5. Such compounds may be used to treat osteoporosis or multiple myeloma..

Topical composition with vitamin d3

The topical composition with vitamin d3 includes vitamin d3, one or more aromatic oils, and aloe vera gel. Vitamin d3 is soluble in aromatic oils, and aloe vera gel enables transport through the stratum corneum so that the composition may be used for fulfilling daily requirements, treatment of bone conditions, such as rickets and osteomalacia, and supportive therapy in osteopenia and osteoporosis.

Ron inhibitors for use in preventing and treating bone loss

Provided herein are methods for inhibiting osteolysis or treating osteoporosis in a subject in need thereof, the method including administering to the subject at least one ron inhibitor. The osteolysis may be caused by a condition selected from the group consisting of cancer, inflammation, and cyst.
University Of Utah Research Foundation



Steoporosis topics:
  • Steoporosis
  • Osteoporosis
  • Breast Cancer
  • Dysfunction
  • Rheumatoid Arthritis
  • Endothelial Dysfunction
  • Endothelial
  • Nephropathy
  • Inflammation
  • Congestive Heart Failure
  • Hypertension
  • Bone Resorption
  • Resorption
  • Cardiovascular
  • Prostate Cancer


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Steoporosis for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Steoporosis with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.246

    file did exist - 2467

    1 - 1 - 52